Prostate Cancer

RNA interference-directed knockdown inhibits prostate cancer

Published in Gene Therapy Weekly, December 15th, 2005

According to recently published research from the United States, RNA interference-directed knockdown of urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.

"The invasive ability of tumor cells plays a key role in prostate cancer metastasis and is a major cause of treatment failure," wrote S.M. Pulukuri and colleagues, University of Illinois.

"uPA- and uPAR-mediated signaling have been implicated in tumor cell invasion, survival, and metastasis in a variety of cancers," scientists in the United States report.

"This...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-12-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry